Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

10 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NUDBepFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHMO|IhcA>? NWXu[5VPTE2VTx?= MWnJR|UxRTBwMECwNFch|ryP NYC5d24{OTd7NU[wPFA>
K562 M1fmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX63NkBp NIXjVVhFVVOR M33FZmlEPTB;MD6wNFEh|ryP Ml:3NVc6PTZyOEC=
M07e MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzoRpk4OiCq MmT0SG1UVw>? MVvJR|UxRTBwMECxNkDPxE1? MVKxO|k2PjB6MB?=
ALL3 Mn30R5l1d3SxeHnjJGF{e2G7 NEKzSZAxNjIQvF2= MlrSO|IhcA>? MYXEUXNQ NYDmTHl1UUN3ME2wMlAxODRizszN MV:xPVg5QTV2MB?=
CML MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrpNlAhdWmw NWXYT5RVTE2VTx?= M1TLc2lEPTB;MD6wNFEh|ryP NHPXSFcyQTJzOUCxOi=>
BA/F3 NYLYepZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\r[Io4OiCq NV;zOo1YTE2VTx?= NWi1R5N5UUN3ME22MlU5QSEQvF2= M13TUFI{ODh6NkS0
BA/F3 NEPJSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[2U3A4OiCq NEjMbGRFVVOR MYrJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= M{TkSFI{ODh6NkS0
BA/F3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvIcFM4OiCq M4jRVWROW09? NI\LRXdKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP Ml3KNlMxQDh4NES=
BA/F3 NWjxXZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe3NkBp NX7ielFCTE2VTx?= MUTJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? Mnu2NlMxQDh4NES=
BA/F3 MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXHSW84OiCq NHXkb3JFVVOR NYe0c2tSUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= MnviNlM{ODF5MEO=
BA/F3 NXPnXVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[3NkBp NFfsR|hFVVOR MkPZTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? M{S0cVI{OzBzN{Cz
BA/F3 M3XDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH1UoJMPzJiaB?= MnvkSG1UVw>? MonXTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? NUL3dXhvOjN|MEG3NFM>
BA/F3 NG\JOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBp MmHqSG1UVw>? NEjwc5JKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCTMkWyTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA5|ryP MnfjNlM{ODF5MEO=
BA/F3 M1freWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fD[VczKGh? MkT4SG1UVw>? NWfOS4VVUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= M2j1S|I{OzBzN{Cz
BA/F3 NYH2NGxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[3NkBp M3rzU2ROW09? NV7oNGF6UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? MlT4NlM{ODF5MEO=
BA/F3 M2G3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCcnU5PzJiaB?= Mo\BSG1UVw>? NIPpU45KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?= Ml7GNlM{ODF5MEO=
BA/F3 M4rkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS5SoY4OiCq M3riVGROW09? NIrWWllKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? NWPDXG1jOjN|MEG3NFM>
BA/F3 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonjO|IhcA>? M1rjZmROW09? NXPQZZJsUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN M3y1UlI{OzBzN{Cz
T cell Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly4O|IhcA>? NXLCN5VGTE2VTx?= NEXESXFKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>? M4\QSFE4OTV2NUGy
WiDr MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonOO|IhcA>? MX;EUXNQ MX\JR|UxRTBwMEWyJO69VQ>? NEnvcHgyPTZzNUWxNi=>
PC3 NYDvO|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfqO|IhcA>? MVTEUXNQ NFTzVpNKSzVyPUCuNFA6PCEQvF2= M2L4NlE2PjF3NUGy
MDA-MB-231 M17N[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r2XVczKGh? NYKwVVRXTE2VTx?= NILuOZBKSzVyPUCuNFEzKM7:TR?= M2\OSVE2PjF3NUGy
Hs578T NIDVOmdEgXSxdH;4bYMhSXO|YYm= Mn3CO|IhcA>? NHPGfYpFVVOR NVfHO|VQT0l3ME2wMlA{KM7:TR?= Mn31NlQxOTV|Mke=
HMEC M4jlfGN6fG:2b4jpZ{BCe3OjeR?= NGPSS204OiCq M1TsfWROW09? NETOW4hIUTVyPUGuPEDPxE1? Mny2NlQxOTV|Mke=
DU145 NITabG1EgXSxdH;4bYMhSXO|YYm= MmPCO|IhcA>? NXL5VlY4TE2VTx?= MXzHTVUxRTBwMU[g{txO NHHocGEzPDBzNUOyOy=>
U251 MXnDfZRwfG:6aXOgRZN{[Xl? MnTjO|IhcA>? Mo\4SG1UVw>? MVvHTVUxRTJwOEGg{txO NHTyR20zPDBzNUOyOy=>
NCI60 M1K3S2N6fG:2b4jpZ{BCe3OjeR?= MkLxO|IhcA>? NGHy[mdFVVOR M4GzbWdKPTB;NT63JO69VQ>? M2TuV|I1ODF3M{K3
MALME-3M MXXDfZRwfG:6aXOgRZN{[Xl? M3zwOlczKGh? NVPTdnZ4TE2VTx?= MUHHTVUxRTZwNkGg{txO M4jyRVI1ODF3M{K3
KM12 M4L5eGN6fG:2b4jpZ{BCe3OjeR?= MlHxO|IhcA>? M1zUVGROW09? NWHCfYNCT0l3ME23MlQ1KM7:TR?= M2nQcVI1ODF3M{K3
SW620 MmPFR5l1d3SxeHnjJGF{e2G7 NFT4S3M4OiCq M{CwTWROW09? MknRS2k2OD16LkSzJO69VQ>? NWK3SXF5OjRyMUWzNlc>
RXF 393NL NHTPNnREgXSxdH;4bYMhSXO|YYm= MYK0JIRigXN? MVXEUXNQ MWHJR|UxRTBwMEKxO{DPxE1? NH\XNYczOzJ3M{C3OC=>
LXFA 983L NV\FbHlyS3m2b4TvfIlkKEG|c3H5 NXLRTHJwPCCmYYnz Ml7PSG1UVw>? NUPSeXRLUUN3ME2wMlA2PjVizszN MoHqNlMzPTNyN{S=
PRXF DU145 NFntN3VEgXSxdH;4bYMhSXO|YYm= NH7SUZU1KGSjeYO= NHzpfXRFVVOR NFzDNnNKSzVyPUCuNFYzOyEQvF2= NITWbY4zOzJ3M{C3OC=>
PAXF 1657L NUjMe4pOS3m2b4TvfIlkKEG|c3H5 MmDqOEBl[Xm| NXPNN|hjTE2VTx?= M3W1eWlEPTB;MD6xNlEh|ryP NYX5S3hbOjN{NUOwO|Q>
CXF 1103L NXP1eVNoS3m2b4TvfIlkKEG|c3H5 NHyyNXo1KGSjeYO= NX\KcZR6TE2VTx?= NYPp[IFTUUN3ME20MlM3KM7:TR?= NWe1ZlNlOjN{NUOwO|Q>
GXF251L MYLDfZRwfG:6aXOgRZN{[Xl? M4rYe|Qh\GG7cx?= MoTrSG1UVw>? MWnJR|UxRTJwMkWg{txO NH3qdVkzOzJ3M{C3OC=>
NCI-H23 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX63NkBp NEm1U5ZFVVOR MYHJR|UxRTJwMkeg{txO Mlv5NlM2OjFyMkC=
HCT116 M37Icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy3NkBp M2X4RmROW09? NVXzXGl1UUN3ME2yMlMh|ryP Mn:1NlM2OjFyMkC=
MCF7 NFvZ[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe3NkBp MnPZSG1UVw>? NYrWPJQ5UUN3ME2yMlU4KM7:TR?= MV2yN|UzOTB{MB?=
NCI-H460 NHHW[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jW[FczKGh? Mnr1SG1UVw>? MVXJR|UxRThwOUmg{txO M2njb|I{PTJzMEKw
DLD1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Fdo1pPzJiaB?= MX7EUXNQ MXnJR|UxRTRwNjFOwG0> MYmyN|U3Pzl4MB?=
NCI-H661 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjCO|IhcA>? Mn;CSG1UVw>? M4TFOGlEPTB;Nz64JO69VQ>? NX7KdFB2OjN3Nke5OlA>
A549 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7YO|IhcA>? MYDEUXNQ MkHITWM2OD16LkKg{txO MoHBNlM2Pjd7NkC=
U937 NHvoSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp M1W3cGROW09? M3X3dmlEPTB;MUKuNkDPxE1? M{nDXFI{PTZ5OU[w
HEK293 MVnGeY5kfGmxbjDBd5NigQ>? NHToOoEyOMLizszN MkTMSG1UVw>? MUjJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= MViyNlc4ODZzMB?=
HUVEC M3i1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrFNmwxNjF3wrFOwG0> NYHqXmg5PzJiaB?= M3K0NmROW09? MVrJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= Ml74NlI5PTN7OUO=
HUVEC MnnwSpVv[3Srb36gRZN{[Xl? MX2xOeKh|ryP MWS3NkBp NXjoXWhbTE2VTx?= M2jPOmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO NXjPenM6OjJ6NUO5PVM>
Plasmodium falciparum MmO3SpVv[3Srb36gRZN{[Xl? M1nRWVExyqEQvF2= NGPo[5oyPSCvaX6= MkPXSG1UVw>? MlPRTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO M4LZZ|I1PTVyM{Ow
PC3 NHLJT|dHfW6ldHnvckBCe3OjeR?= MUKwMlEh|ryP NUT4OlhkPSCq NXvSVWpqTE2VTx?= NEfCW4xKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NYTYPZpiOTl2NkK5O|U>
DU145 MY\GeY5kfGmxbjDBd5NigQ>? MUiwMlEh|ryP NEXyZ5Y2KGh? NHviR5NFVVOR MXvJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MmC5NVk1PjJ7N{W=
PC3 MoTTT4lv[XOnIFHzd4F6 NVHKU5Q6OC5zIN88US=> NInEcGY2KGh? NIrWSXVFVVOR NH2w[pJKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N MWmxPVQ3Ojl5NR?=
DU145 NFvxepZMcW6jc3WgRZN{[Xl? NFHTZooxNjFizszN NETPfm42KGh? MV;EUXNQ NFz1ZmRKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MUSxPVQ3Ojl5NR?=
PC3 NWKwd21qU2mwYYPlJGF{e2G7 NGnzc2gxNjFizszN MkTnOUBp MkOxSG1UVw>? NIHJOIVKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? MVWxPVQ3Ojl5NR?=
DU145 M2HKNmtqdmG|ZTDBd5NigQ>? NGnCZ5UxNjFizszN MoHHOUBp MYPEUXNQ NW\iVoxNUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= MoHlNVk1PjJ7N{W=
Huh7 MYjBcpRqfmm{YXygRZN{[Xl? MX:yMlUh|ryP MmHFOEBl[Xm| MUnEUXNQ MX3Jcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MV6xO|M3ODZ5Nh?=
C6/36 NIf4bIRCdnSrdnnyZYwhSXO|YYm= M2jRblIvPSEQvF2= MoO0OEBl[Xm| NFzIV3hFVVOR NF3UOJpKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MUSxO|M3ODZ5Nh?=
U937 MknzSpVv[3Srb36gRZN{[Xl? NVuzUmMyOSEQvF2= M3P5TlEhcA>? M2XOXmROW09? NYTWUHVLWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NUjEe5BLOTd4OESwPVk>
U937 NXzQU5F1TnWwY4Tpc44hSXO|YYm= NX\LPHVUOSEQvF2= NWLEbGRJOSCq NVrGO3E{TE2VTx?= NYDJU4d4WmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NF[4WYkyPzZ6NEC5PS=>
murine mast cell M17BOGZ2dmO2aX;uJGF{e2G7 MUSxJO69VQ>? MWGyOEBp NWntWlJFTE2VTx?= NVP4SmZ3UW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= M4Hjb|E4Pjh2MEm5
BV-173 NULlSHh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrt[45SUUN3ME2wMlAxODByMEGwPUDPxE1? NVftXZJ3W0GQR1XS
K-562 NF\jVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTKOplGUUN3ME2wMlAxODByMEK2OkDPxE1? MkW0V2FPT0WU
BL-70 NYLlSm02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPGTWM2OD1yLkCwNFAxODh{MjFOwG0> M3HnbHNCVkeHUh?=
EM-2 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zOXGlEPTB;MD6wNFAxODFyODFOwG0> M3fEV3NCVkeHUh?=
LAMA-84 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjXdFBKSzVyPUCuNFAxODB|MkGg{txO NGHQbopUSU6JRWK=
MEG-01 M{TH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ETWM2OD1yLkCwNFAxQThizszN MknrV2FPT0WU
EoL-1-cell MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO2S4I4UUN3ME2wMlAxODBzM{Gg{txO MnLWV2FPT0WU
CTV-1 NXj3d5Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yTWM2OD1yLkCwNFA1ODRizszN MUXTRW5ITVJ?
TE-15 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P1NWlEPTB;MD6wNFU5QSEQvF2= MVzTRW5ITVJ?
NOS-1 M1fzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHBdG1KSzVyPUCuNFA3OTNizszN M3[0dHNCVkeHUh?=
D-336MG NIrUOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHTepdKSzVyPUCuNFA3OyEQvF2= NGXZU2RUSU6JRWK=
LB1047-RCC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLNTWM2OD1yLkCwPVg6KM7:TR?= MkLRV2FPT0WU
LB996-RCC Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;pVIRTUUN3ME2wMlAxQTlzIN88US=> MXLTRW5ITVJ?
SW982 M1TDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfBSHdJUUN3ME2wMlAyOTF3IN88US=> MoT6V2FPT0WU
TK10 NUP1ZZFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEGxO|Qh|ryP NILT[2lUSU6JRWK=
A704 NHrid4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LxUGlEPTB;MD6wNVQ6OSEQvF2= MmfDV2FPT0WU
TE-8 NVKyVHhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\6NYpJUUN3ME2wMlAyPTd4IN88US=> MmLWV2FPT0WU
DOHH-2 M2G4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XTcGlEPTB;MD6wNVcyQSEQvF2= NWTDPW54W0GQR1XS
HOP-62 M{XBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO5TWM2OD1yLkCxPFM1KM7:TR?= NWPKWXA2W0GQR1XS
TE-12 M3LVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEG4OlEh|ryP MXLTRW5ITVJ?
KGN NFXsR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD1yLkCxPVQzKM7:TR?= NYn6PHB4W0GQR1XS
NCI-H1648 NYj0RZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXhTWM2OD1yLkCyNFEyKM7:TR?= NYfQSJdJW0GQR1XS
OS-RC-2 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLkTXdKSzVyPUCuNFIxOyEQvF2= M2LsSnNCVkeHUh?=
GB-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\WTWM2OD1yLkCyNVU4KM7:TR?= MVPTRW5ITVJ?
RXF393 NIHqSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEKzOVch|ryP M{LPPXNCVkeHUh?=
LC-2-ad MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j6V2lEPTB;MD6wNlU5PiEQvF2= MVTTRW5ITVJ?
KS-1 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEK3N{DPxE1? NXnlOYt[W0GQR1XS
ETK-1 M4fobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\yTWM2OD1yLkCyPFMzKM7:TR?= NVL4[mpjW0GQR1XS
SW954 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Je21QUUN3ME2wMlAzQTJ5IN88US=> NX21[|hDW0GQR1XS
Becker NW\IOJBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36yXGlEPTB;MD6wN|AxOyEQvF2= M{DFO3NCVkeHUh?=
MZ1-PC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jBWGlEPTB;MD6wN|EyQSEQvF2= MmrQV2FPT0WU
ES6 NXy5O3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LxRmlEPTB;MD6wN|E6OyEQvF2= MVvTRW5ITVJ?
KURAMOCHI MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33vbGlEPTB;MD6wN|Q5PyEQvF2= MkLyV2FPT0WU
CGTH-W-1 NVTs[nJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\3TWM2OD1yLkCzOVQ5KM7:TR?= MojTV2FPT0WU
VA-ES-BJ MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEO5NFIh|ryP NF3IVZRUSU6JRWK=
LXF-289 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\aTWM2OD1yLkCzPVU3KM7:TR?= NUH4WpNIW0GQR1XS
MPP-89 NVnWdppRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LhZWlEPTB;MD6wOFA1QSEQvF2= NH;DSJpUSU6JRWK=
SW872 M{TTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rKb2lEPTB;MD6wOFE3OSEQvF2= NEfmU4xUSU6JRWK=
SNB75 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMES0N|Uh|ryP NIjPVW5USU6JRWK=
PSN1 NVvZWopoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMES0O|Qh|ryP NFnaWpdUSU6JRWK=
LB831-BLC M4G2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHRPG5KSzVyPUCuNFQ3ODlizszN MnX1V2FPT0WU
MFH-ino M3ywTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMES3NlQh|ryP NHHYW49USU6JRWK=
TGBC24TKB NWPCcW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn5PXdKSzVyPUCuNFQ4PjFizszN NGHCOYVUSU6JRWK=
A388 M{CwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkntTWM2OD1yLkC1NFk2KM7:TR?= NYjieYFyW0GQR1XS
BB30-HNC M3;lSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3sSJN6UUN3ME2wMlA2PDN5IN88US=> NV:3enBwW0GQR1XS
GI-ME-N M1W1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW1bIFmUUN3ME2wMlA3OTF6IN88US=> M1PvWnNCVkeHUh?=
TGBC1TKB NWjXflRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i0XGlEPTB;MD6wOlE3PCEQvF2= MnntV2FPT0WU
TE-10 NWO5NFJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwME[zOVch|ryP NWLQbplNW0GQR1XS
A498 M{nSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPvTWM2OD1yLkC3Nlg1KM7:TR?= M1;x[nNCVkeHUh?=
TE-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHqTWM2OD1yLkC3PFU5KM7:TR?= Mn7EV2FPT0WU
BB65-RCC NF31PIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEiyNlch|ryP NEPBPJhUSU6JRWK=
C2BBe1 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEizNFgh|ryP NYTDNVBvW0GQR1XS
NCI-H747 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjhSokzUUN3ME2wMlA5OzZ{IN88US=> NGLifJRUSU6JRWK=
IST-MES1 NWD2fVlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLHTWM2OD1yLkC4OVUzKM7:TR?= NUnTR2ZOW0GQR1XS
KALS-1 M{P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm0OVdKSzVyPUCuNFk1QSEQvF2= NVnVeZo1W0GQR1XS
GCIY MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHqdoZKSzVyPUCuNFk3PTZizszN M1fkT3NCVkeHUh?=
RL95-2 M4DacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7GeFlIUUN3ME2wMlExOzhizszN M3jxZXNCVkeHUh?=
TE-1 M1nwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uxSGlEPTB;MD6xNFU1KM7:TR?= NXXidnVDW0GQR1XS
NCI-H1355 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TzbGlEPTB;MD6xNVAzQCEQvF2= MmrTV2FPT0WU
SW962 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP5TWM2OD1yLkGxNlkzKM7:TR?= M4[xWXNCVkeHUh?=
KLE NU\rOphIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zWfWlEPTB;MD6xNVMyPyEQvF2= MYfTRW5ITVJ?
MC116 NWn0ZoZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknOTWM2OD1yLkGxOFEh|ryP NGG1UJNUSU6JRWK=
NMC-G1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Mc3FYUUN3ME2wMlEyPjB4IN88US=> MXHTRW5ITVJ?
KU812 MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW3TWM2OD1yLkGxPFg{KM7:TR?= NWHFfYFQW0GQR1XS
COLO-829 M{LBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL5TWM2OD1yLkGyNlE{KM7:TR?= NYf1fIRjW0GQR1XS
NTERA-S-cl-D1 M3TKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMUKyPFMh|ryP M1\oeHNCVkeHUh?=
IST-MEL1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M165SGlEPTB;MD6xN|Q2KM7:TR?= NF3qXIRUSU6JRWK=
MLMA Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjn[YhrUUN3ME2wMlE1ODN{IN88US=> MlOxV2FPT0WU
LS-123 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPWXoV5UUN3ME2wMlE1ODZ2IN88US=> MXHTRW5ITVJ?
LB2518-MEL MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMUSxOlIh|ryP NGKwVIpUSU6JRWK=
NB69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUS0N|Yh|ryP M1G0bHNCVkeHUh?=
8-MG-BA NVvtS456T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnhRY1rUUN3ME2wMlE2PDV6IN88US=> MkWzV2FPT0WU
K5 NYH1TmhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfYTWM2OD1yLkG2OFg6KM7:TR?= MnjJV2FPT0WU
KINGS-1 NVz4[HhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HEW2lEPTB;MD6xOlY3PiEQvF2= M32yb3NCVkeHUh?=
SF268 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMUe0NFQh|ryP M3fpcnNCVkeHUh?=
PF-382 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULufIxKUUN3ME2wMlE4Pjd6IN88US=> MoThV2FPT0WU
SH-4 NVO4VYRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\6TWM2OD1yLkG4OFE{KM7:TR?= M2HC[3NCVkeHUh?=
NALM-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2faNWlEPTB;MD6xPVI6PSEQvF2= NHHTWGRUSU6JRWK=
CP66-MEL M4C5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvSTWM2OD1yLkG5OVMyKM7:TR?= MVfTRW5ITVJ?
697 NYHLVW1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLSY5JUUN3ME2wMlE6QTh5IN88US=> MXXTRW5ITVJ?
CP67-MEL NFK2W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLlTWM2OD1yLkKwOFg5KM7:TR?= MoHqV2FPT0WU
DSH1 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLpTWM2OD1yLkK0NFAyKM7:TR?= MlOxV2FPT0WU
HCE-4 NYTSZnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[yfGlEPTB;MD6yOlQ{QSEQvF2= NF31enZUSU6JRWK=
MZ2-MEL Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfKXohNUUN3ME2wMlI5PTN5IN88US=> M3vsbnNCVkeHUh?=
BL-41 NEDu[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon2TWM2OD1yLkK5NVI{KM7:TR?= NX33VIlKW0GQR1XS
HUTU-80 NXrieGU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnXdoRKSzVyPUCuN|E1OiEQvF2= MYHTRW5ITVJ?
LOXIMVI Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwM{G1NFMh|ryP MVfTRW5ITVJ?
no-10 NECwfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwM{G5N|Eh|ryP NFTjPXpUSU6JRWK=
KARPAS-422 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLDT2xqUUN3ME2wMlM{QTl5IN88US=> NFPacYFUSU6JRWK=
SW684 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwM{S5PEDPxE1? MWHTRW5ITVJ?
SF126 NGXBXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwM{W0NUDPxE1? MVXTRW5ITVJ?
D-263MG NUTpSWN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmxWm9KSzVyPUCuN|YzOjRizszN NH3pUZVUSU6JRWK=
OVCAR-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\MV3FCUUN3ME2wMlM4PDN|IN88US=> M3nEXXNCVkeHUh?=
BB49-HNC M3\kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTOTWM2OD1yLkO4OVk6KM7:TR?= M12zb3NCVkeHUh?=
ONS-76 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;YN4dHUUN3ME2wMlQzQTVzIN88US=> MYfTRW5ITVJ?
MZ7-mel NXXNV5hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwNEe5NVEh|ryP M{H1[nNCVkeHUh?=
RCC10RGB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwNEmxNUDPxE1? M3zQdnNCVkeHUh?=
BOKU MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLEWFhKSzVyPUCuOFkyOzNizszN NFTyO4dUSU6JRWK=
no-11 M13YRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr1TWM2OD1yLkWwNlI5KM7:TR?= M3ftPXNCVkeHUh?=
IST-SL2 NVfaOYxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNUCzNFIh|ryP MkfLV2FPT0WU
RKO NIq4bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNUK5OlYh|ryP MlPhV2FPT0WU
HT-144 M{LMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTZS4d7UUN3ME2wMlU{PjB7IN88US=> M3\ZZ3NCVkeHUh?=
NCI-H446 M4PkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jmVWlEPTB;MD62Nlc3KM7:TR?= M3y2eHNCVkeHUh?=
QIMR-WIL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjpTWM2OD1yLkewOlI6KM7:TR?= NFvJ[mdUSU6JRWK=
MHH-PREB-1 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfBdolDUUN3ME2wMlc1PDZ7IN88US=> NIfIPIFUSU6JRWK=
EW-16 NEG3UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwN{[xO|gh|ryP NWLKTZQzW0GQR1XS
EW-24 NUHK[Ih4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\LTWM2OD1yLke4NVY2KM7:TR?= MVXTRW5ITVJ?
LB373-MEL-D Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorkTWM2OD1yLkiyOVA5KM7:TR?= NVS2OIFrW0GQR1XS
TE-9 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwOEe1N|Ih|ryP MljMV2FPT0WU
A3-KAW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XzPGlEPTB;MD65PFQ2OiEQvF2= M{TWSnNCVkeHUh?=
A101D NV\CUYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrBUIZMUUN3ME2xMlA{ODR|IN88US=> MnrVV2FPT0WU
OCUB-M NWiyUJd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\uTWM2OD1zLkC0OFEzKM7:TR?= Mlm3V2FPT0WU
ES4 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTuTWM2OD1zLkC1NVQ2KM7:TR?= M4Hte3NCVkeHUh?=
TE-6 M3PBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm0colKSzVyPUGuNlEzOjZizszN NH24eJZUSU6JRWK=
D-502MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXtWWJwUUN3ME2xMlI{Ozd4IN88US=> NFjuO2FUSU6JRWK=
KNS-42 NXvqWINHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG5dGZwUUN3ME2xMlI1PDF{IN88US=> MYLTRW5ITVJ?
SNU-C2B MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPPTWM2OD1zLkOwOVg6KM7:TR?= NUD1Zld[W0GQR1XS
NCI-H1838 NHrtfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHZTWM2OD1zLkOwO|M{KM7:TR?= MWLTRW5ITVJ?
NKM-1 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\qTWM2OD1zLkOwPFU6KM7:TR?= MXTTRW5ITVJ?
GI-1 NWfBNXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nvXWlEPTB;MT6zOlIzKM7:TR?= NXvvZnVFW0GQR1XS
NB5 M4nidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDQTWM2OD1zLkO5PFI4KM7:TR?= MVvTRW5ITVJ?
CAS-1 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwNEC5PVIh|ryP NV\sdJM5W0GQR1XS
HCE-T NV\keWxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[5RpRKSzVyPUGuOVY4OTRizszN M2\ZVHNCVkeHUh?=
SBC-1 NXzDT2w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:5TWM2OD1zLkW3PVg1KM7:TR?= M3nY[HNCVkeHUh?=
JiyoyeP-2003 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkfINKSzVyPUGuO|M1PjZizszN MlzBV2FPT0WU
TE-5 NVfkT3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwN{mxN|kh|ryP MoDzV2FPT0WU
CAN NYTtUpdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\ETWM2OD1zLkiyNlUzKM7:TR?= MlvHV2FPT0WU
SK-UT-1 NInE[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjSWHRKSzVyPUKuNVY3QTNizszN NHjMOIlUSU6JRWK=
JVM-2 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwM{[yPFQh|ryP M2j3eXNCVkeHUh?=
LB771-HNC NGHQV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHRN3ZKSzVyPUKuOVc2PTFizszN M3XDS3NCVkeHUh?=
NCCIT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJwOE[2NVYh|ryP MkiyV2FPT0WU
NCI-H2126 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q2V2lEPTB;Mj64O|U2OiEQvF2= MUfTRW5ITVJ?
Calu-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[3bnY2UUN3ME2zMlA2PzRzIN88US=> NVjTNlIzW0GQR1XS
SK-LMS-1 NWPjRVR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPhNI5KSzVyPUOuNVE5QDZizszN NILOT3RUSU6JRWK=
ARH-77 M3T0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNwNE[5NVUh|ryP M2jmZXNCVkeHUh?=
NB17 M2XGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjjTWM2OD1|Lk[zPFQ4KM7:TR?= MW\TRW5ITVJ?
A253 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37rS2lEPTB;Mz63N|I1PiEQvF2= NHjwT5JUSU6JRWK=
OPM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTRwMke2PFUh|ryP NWnvbXlyW0GQR1XS
MV-4-11 M{TrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rtV2lEPTB;ND6zOlQ2PCEQvF2= MXPTRW5ITVJ?
SR MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwNEm5OVQh|ryP MUjTRW5ITVJ?
KG-1 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjQNGlKUUN3ME20MlYxQDR3IN88US=> NEf4Um9USU6JRWK=
OCI-AML2 M1XFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD13Lki2NVU1KM7:TR?= NETiSYhUSU6JRWK=
D-247MG NFKxPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjQTWM2OD14LkGyOVE6KM7:TR?= MVPTRW5ITVJ?
DJM-1 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDDd41KSzVyPU[uOFg2PThizszN NH3NT3lUSU6JRWK=
RPMI-6666 NHr2VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX74OJE6UUN3ME23MlI4ODZ5IN88US=> NYHlTXluW0GQR1XS
KARPAS-45 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Vb2dKSzVyPUeuOVE3PzFizszN NWLienBoW0GQR1XS
LP-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvoTWM2OD15LkW0O|gzKM7:TR?= NFnnbY1USU6JRWK=
RS4-11 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTdwNkW3PFch|ryP NV3vZZdJW0GQR1XS
DU-4475 NH7kbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTR[m1KSzVyPUiuNlE3PTJizszN M3;hSHNCVkeHUh?=
MONO-MAC-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRThwMkewOlYh|ryP NXrBW40xW0GQR1XS
NCI-SNU-16 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\tWlN3UUN3ME24MlU3OTJ6IN88US=> NGrkdHlUSU6JRWK=
SJSA-1 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3zUXEzUUN3ME24MlczQDB3IN88US=> MlHKV2FPT0WU
MMAC-SF NWH0[m5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Pz[GlEPTB;OD63PVMxPyEQvF2= MnTJV2FPT0WU
SK-NEP-1 NV3NPYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13E[mlEPTB;OD64PVE2PSEQvF2= NVzBepdKW0GQR1XS
J-RT3-T3-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\1NodKSzVyPUiuPVY2OjlizszN MXfTRW5ITVJ?
SKM-1 M2K4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ruXGlEPTB;OT6wNVc{PCEQvF2= M3\sTXNCVkeHUh?=
LB2241-RCC NV\jOpJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX1TJR1UUN3ME25MlAzODF{IN88US=> NV;DeIRUW0GQR1XS
SIG-M5 NIHZWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjYTWM2OD17LkCyOFk{KM7:TR?= NHLqe|dUSU6JRWK=
EVSA-T NXTLTGUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPN[4dZUUN3ME25MlI4Pzl|IN88US=> NEPwUIRUSU6JRWK=
GT3TKB NXWxV3NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX5b3RKSzVyPUmuN|U2PDZizszN M3LMeHNCVkeHUh?=
NB6 NXzSdXU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTlwOUKyOVkh|ryP MYjTRW5ITVJ?
EHEB NETOSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7kXZkzUUN3ME2xNE4xPjV4IN88US=> MYjTRW5ITVJ?
HEL NGHyO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfNOo5wUUN3ME2xNE41Pzd4IN88US=> M2HXTHNCVkeHUh?=
ALL-PO MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XWWGlEPTB;MUCuO|k{QCEQvF2= M2XWe3NCVkeHUh?=
TGW M3nC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFzLkK4Nlgh|ryP MnzZV2FPT0WU
BC-3 M{HQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T5VmlEPTB;MUKuNVE{QCEQvF2= NX\VXI9IW0GQR1XS
IA-LM NX7WT2dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK1TWM2OD1zMj60OFQ2KM7:TR?= NIjJdFNUSU6JRWK=
UACC-257 NXTiTHVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF{LkmxPVgh|ryP MVHTRW5ITVJ?
KP-N-YS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGwXmIyUUN3ME2xNk46Ojh|IN88US=> M2fLWnNCVkeHUh?=
Raji M3jWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PLcWlEPTB;MUOuO|Q6PyEQvF2= MmPXV2FPT0WU
SF539 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF|Lki1OVch|ryP MmfFV2FPT0WU
DMS-153 NFL1VXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vaVmlEPTB;MUSuNFAzQCEQvF2= NH;Fe4ZUSU6JRWK=
L-540 M33VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\tXmlEPTB;MUWuNFY4OiEQvF2= NVXHOJF[W0GQR1XS
MN-60 NILBWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHBTWM2OD1zNT6xPVc6KM7:TR?= MUDTRW5ITVJ?
RPMI-8866 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD4UHRKSzVyPUG3MlQ1PTRizszN MV;TRW5ITVJ?
NCI-H510A NEHXd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnRNZRKSzVyPUG5MlM6PzNizszN M1jEd3NCVkeHUh?=
NB13 M{HIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr6TWM2OD1zOT60PFc4KM7:TR?= M2PNWHNCVkeHUh?=
HAL-01 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF7Lke1OFMh|ryP NF\pXFRUSU6JRWK=
NCI-H720 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rHbWlEPTB;MkCuNlc{OyEQvF2= MV\TRW5ITVJ?
REH M32wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTISXRRUUN3ME2yNE43OzV5IN88US=> NF2wbZpUSU6JRWK=
KNS-81-FD M4XSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzVO25xUUN3ME2yN{4yPDZizszN MY\TRW5ITVJ?
HC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O5WGlEPTB;MkSuOVU2OSEQvF2= NVPD[XZxW0GQR1XS
NCI-H2141 M1jI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrBfZFKSzVyPUK0Mlc4PTRizszN MVfTRW5ITVJ?
MOLT-4 NIHkR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7oTWM2OD1{Nj62O|U{KM7:TR?= MkPxV2FPT0WU
OMC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LnT2lEPTB;MkeuNVQzOiEQvF2= M3LKVnNCVkeHUh?=
LC-1F M1vOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO4RZhKSzVyPUK3MlMzPDVizszN Mlq1V2FPT0WU
NCI-H1304 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrHZmpGUUN3ME2yPE4yPjJ6IN88US=> MnvVV2FPT0WU
BC-1 NULYR5JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[z[olKSzVyPUK4MlY2OSEQvF2= MXXTRW5ITVJ?
NCI-H64 M{HnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XtSmlEPTB;MkmuOlI2OyEQvF2= MXXTRW5ITVJ?
MOLT-16 NGC1VJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPKTWM2OD1{OT62NlkzKM7:TR?= M1LXXXNCVkeHUh?=
U-87-MG MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPlO3duUUN3ME2zNE44PjZizszN NHjLWHZUSU6JRWK=
GAK NX;tbmJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zl[mlEPTB;M{GuNlY5PiEQvF2= Mlj4V2FPT0WU
ES8 NHKwVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN{LkGyOVIh|ryP MU\TRW5ITVJ?
HCC1599 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlryTWM2OD1|Mj6zN|I2KM7:TR?= M133SHNCVkeHUh?=
EB-3 NF3hfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTN2LkOxNVch|ryP MnLOV2FPT0WU
HCC1187 M3OxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN3LkiwOVIh|ryP NIHNOFNUSU6JRWK=
SK-PN-DW NUHyO4V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjzbJdEUUN3ME2zOk4yQTR|IN88US=> MVrTRW5ITVJ?
JVM-3 M1voR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjlTWM2OD1|Nz6yN|M5KM7:TR?= NHfw[nZUSU6JRWK=
HCC2157 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr4ZVFKSzVyPUO3Mlk6PDZizszN MV7TRW5ITVJ?
A4-Fuk NF;yUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD1|OD6xNFA6KM7:TR?= NWDQXmxJW0GQR1XS
COR-L279 NVXNeWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXiXYVKSzVyPUSwMlI5PTFizszN MnH2V2FPT0WU
DEL NV\MW3FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXntTohWUUN3ME20NU46ODh4IN88US=> MkfkV2FPT0WU
NCI-H1395 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jjS2lEPTB;NEKuNFE3OyEQvF2= MlfVV2FPT0WU
MHH-NB-11 NE\0cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fJSWlEPTB;NEOuNFgyQCEQvF2= NGf6V45USU6JRWK=
NCI-H2107 NWLRTlI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWwWVNIUUN3ME20N{41QDR4IN88US=> MVrTRW5ITVJ?
NEC8 M172WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7LXW1KSzVyPUS0MlM{PiEQvF2= M2fje3NCVkeHUh?=
COLO-684 NUPwS4ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjXUFBQUUN3ME20Ok4zOjV6IN88US=> MXTTRW5ITVJ?
LS-411N MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGThXYZKSzVyPUS4MlQ4PDhizszN Mm[yV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID